Reckitt Benckiser Focuses On Growth In Emerging Markets

BMI Core View: Emerging markets will drive industry growth and their importance to multinational drugmakers cannot be overstated. BMI's Pharmaceutical Expenditure Model shows that five-year compound annual growth rates (CAGRs) in traditional markets, such as the US, Western Europe and Japan, are all in the low single figures. Meanwhile, the US dollar five-year CAGRs for the main emerging markets - Brazil, Russia, India and China - are expected to post double-digit

To read the full article, please choose one of the following options: